Immuneering Launches Pancreatic Cancer Advisory Board
December 19, 2024 08:00 ET
|
Immuneering Corporation
Immuneering Launches Pancreatic Cancer Advisory Board
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
December 17, 2024 08:00 ET
|
Immuneering Corporation
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
December 12, 2024 08:00 ET
|
Immuneering Corporation
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
November 27, 2024 08:00 ET
|
Immuneering Corporation
Immuneering to Present at the Piper Sandler 36th Annual Healthcare Conference
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 13, 2024 16:05 ET
|
Immuneering Corporation
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
October 15, 2024 08:00 ET
|
Immuneering Corporation
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
September 12, 2024 16:05 ET
|
Immuneering Corporation
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024 08:00 ET
|
Immuneering Corporation
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 06, 2024 16:05 ET
|
Immuneering Corporation
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
July 31, 2024 16:05 ET
|
Immuneering Corporation
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer